Because of the high prevalence of diabetes in this region, which results in high demand for insulin, the North American market dominated the global Insulin Biosimilars market. Furthermore, due to early approval for Insulin Biosimilar in the region's countries, the Europe Insulin Biosimilar market is expected to account for the second largest revenue share in the global market. Over the forecast period, the Asia Pacific market is expected to grow at the fastest rate in terms of revenue. This is due to key players competing on price, as well as the increased number of diabetic patients in this region's countries, which fuels the Insulin Biosimilar market in Asia Pacific.
Read More:
https://knackersblogger.blogspot.com/2022/08/rapid-acting-insulin-analogues-are.html
